RESUMEN
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease associated with a high physical and psychological burden. It is a disorder of the infundibular segment of the pilosebaceous unit, characterized by subcutaneous nodules, abscesses, sinus tracts and scar formation on the intertriginous and apocrine-bearing areas. HS is quite rare in young and prepubertal children. It usually begins after puberty, but several reports of prepubertal HS onset have been described. These cases are strongly linked to hormonal disorders and genetic susceptibility. Specific guidelines for prepubertal patients are still lacking, so further studies are warranted to better delineate a tailored approach. This paper aims to summarize the most significant aspects, as well as the most recent information about the epidemiology, pathogenesis, clinical features, diagnosis, comorbidities and treatment of paediatric HS. In addition, we report our clinical experience in managing HS in a group of eight prepubertal patients based on systemic antibiotics (azithromycin) and zinc oral supplementation.
Asunto(s)
Antibacterianos/uso terapéutico , Hidradenitis Supurativa/tratamiento farmacológico , Azitromicina/uso terapéutico , Niño , Clindamicina/uso terapéutico , Quimioterapia Combinada , Femenino , Predisposición Genética a la Enfermedad , Hidradenitis Supurativa/complicaciones , Hidradenitis Supurativa/epidemiología , Hidradenitis Supurativa/genética , Humanos , Hiperandrogenismo/complicaciones , Hiperinsulinismo/complicaciones , Guías de Práctica Clínica como Asunto , Pubertad Precoz/complicacionesRESUMEN
AIM: Pityriasis alba (PA) is a skin disorder characterized by finely scaly, hypopigmented patches, typical of childhood, that also represents an atopic dermatitis (AD) minor sign according to Hanifin and Rajka criteria. It may be isolated or associated with AD representing, sometimes an atypical manifestation of AD during the long-term follow-up of the disease. Aim of the study was to evaluate of the efficacy and tolerability of AR-GG27® (sorbityl furfural palmitate) cream in the treatment of childhood mild or moderate AD associated with PA. METHODS: The trial is a single center, double-blind, randomized, placebo-controlled study. The study included patients of both sexes, aged between two months and 15 years, suffering from mild and moderate AD always associated with PA. Xerosis was present in all patients. The treatment with topical steroids or topical calcineurin inhibitors (TIMs) had to be suspended for at least 15 days. Any systemic therapy and phototherapy or sun exposure were withdrawn at least 30 days before. Emollients were stopped at least seven days before. During the trial, no other local or systemic treatments were allowed, as well as sun exposure. Patients affected by AD with viral, bacterial or fungal overinfection or patients with diabetes mellitus, severe systemic diseases or intolerance to one or more components of the product were excluded. The primary endpoint was the evaluation of the average change in the Investigator Global Assessment (IGA) after 15 and 30 days of treatment. The second endpoint was the evaluation of severity of three different clinical signs: erythema, excoriation desquamation, using a subjective five-point scale. Changes in pruritus severity was also considered during the entire period of treatment, through the use of a Visual Analogue Scale (VAS). A P<0.05, two tailed was considered as statistically significant. RESULTS: After 15 and 30 days there was a statistically significant difference in the group treated with AR-GG27®, compared to the placebo (respectively, P=0.0007 and P=0.005). After 15 days of treatment, itching was clearly reduced in AR-GG27® treated group compared with the placebo, both in the study population (P=0.01) and in patients where the symptom was present from the beginning (P=0.05). CONCLUSION: AR-GG27® showed a beneficial action associated with high compliance and tolerability in dermatological skin conditions characterized by inflammation and tissue oxidative stress in children, as PA with mild and moderate AD.
Asunto(s)
Dermatitis Atópica/tratamiento farmacológico , Fármacos Dermatológicos/administración & dosificación , Furaldehído/administración & dosificación , Hipopigmentación/tratamiento farmacológico , Palmitatos/administración & dosificación , Pitiriasis/tratamiento farmacológico , Sorbitol/administración & dosificación , Administración Cutánea , Adolescente , Algoritmos , Niño , Preescolar , Dermatitis Atópica/complicaciones , Dermatitis Atópica/diagnóstico , Fármacos Dermatológicos/uso terapéutico , Diagnóstico Diferencial , Método Doble Ciego , Combinación de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Hipopigmentación/diagnóstico , Hipopigmentación/etiología , Lactante , Masculino , Palmitatos/síntesis química , Palmitatos/uso terapéutico , Pitiriasis/clasificación , Pitiriasis/complicaciones , Pitiriasis/diagnóstico , Muestreo , Índice de Severidad de la Enfermedad , Sorbitol/síntesis química , Sorbitol/uso terapéutico , Resultado del TratamientoRESUMEN
BACKGROUND: MAS063DP cream has received marketing authorization in the USA and the EU as a medical device for the relief of symptoms of atopic dermatitis (AD) and contact dermatitis. OBJECTIVE: Review of technical and clinical data in the literature on MAS063DP to evaluate the role that MAS063DP (Sinclair Pharmaceuticals Ltd) holds in the management of patients affected by AD. METHODS: We explored the characteristics and efficacy of the product by a wide-ranging search of the medical and scientific studies in the literature and drew our conclusions also on the basis of our medical practice and knowledge concerning the treatment guidelines and therapy options of AD. CONCLUSION: MAS063DP is a product dermatologists could enroll in the treatment of signs and symptoms of mild-to-moderate AD in adult and pediatric patients.